| Autor: |
Goki, Suda, Atsushi, Nagasaka, Yoshiya, Yamamoto, Ken, Furuya, Kenichi, Kumagai, Mineo, Kudo, Katsumi, Terashita, Tomoe, Kobayashi, Izumi, Tsunematsu, Junichi, Yoshida, Takashi, Meguro, Megumi, Kimura, Jun, Ito, Machiko, Umemura, Takaaki, Izumi, Seiji, Tsunematsu, Fumiyuki, Sato, Yoko, Tsukuda, Masato, Nakai, Takuya, Sho, Mitsuteru, Natsuizaka, Kenichi, Morikawa, Koji, Ogawa, Naoya, Sakamoto |
| Rok vydání: |
2016 |
| Zdroj: |
Hepatology research : the official journal of the Japan Society of Hepatology. 47(11) |
| ISSN: |
1386-6346 |
| Popis: |
Hepatitis C virus (HCV) infection is a risk factor for end-stage renal disease, renal graft failure, and hemodialysis patient mortality. However, the efficacy of direct-acting antiviral therapy for HCV-infected patients with renal impairment is unclear. Additionally, the promising NS5B inhibitor sofosbuvir has not been recommended for patients with severe renal impairment. In this prospective, multicenter study, we evaluated the efficacy and safety of daclatasvir and asunaprevir combination therapy, with a focus on patients with renal impairment.The study included 322 genotype 1 HCV-infected patients who received daclatasvir and asunaprevir combination therapy. The safety and sustained virological response was examined at 12 weeks after the end of treatment and safety was evaluated according to renal function.Of 322 patients, 5% (16/322) and 2.5% (8/322) had chronic kidney disease stage G3b (estimated glomerular filtration rate [eGFR], 30-44 mL/min/1.73 mDaclatasvir and asunaprevir combination therapy for patients with renal dysfunction was highly effective and safe. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Plný text